César Award for Best Poster

Promontory Therapeutics to Present Research on PT-112 in Advanced Non-Small Cell Lung Cancer at the ESMO Immuno-Oncology Congress 2022

Retrieved on: 
Wednesday, November 30, 2022

Abstracts will be published online on the ESMO website at 12:05 a.m. CET on Thursday, Dec. 1, 2022.

Key Points: 
  • Abstracts will be published online on the ESMO website at 12:05 a.m. CET on Thursday, Dec. 1, 2022.
  • Abstracts will also be published online in the ESMO-IO Congress 2022 Abstract Book, a supplement to the official ESMO journal, Immuno-Oncology and Technology (IOTECH).
  • PT-112 represents a highly potent inducer of this immunological form of cancer cell death.
  • Promontory Therapeutics Inc. is a privately held, clinical stage pharmaceutical company focused on small molecule immunotherapy.

Promontory Therapeutics Reports PT-112's Effects on Human Prostate Cancer Cell Mitochondria at the 34th EORTC-NCI-AACR Symposium

Retrieved on: 
Wednesday, October 26, 2022

"Ongoing studies into PT-112's ability to induce immunogenic cell death and cancer cell organelle stresses have been encouraging and support our elucidation of the drivers of PT-112's validated immunogenic cancer cell death," said Promontory co-founder and Chief Operating Officer Matthew Price.

Key Points: 
  • "Ongoing studies into PT-112's ability to induce immunogenic cell death and cancer cell organelle stresses have been encouraging and support our elucidation of the drivers of PT-112's validated immunogenic cancer cell death," said Promontory co-founder and Chief Operating Officer Matthew Price.
  • The non-clinical study of PT-112 was designed to continue the characterization of PT-112's effects on mitochondria in a panel of human prostate cancer cell lines.
  • Key study findings included:
    Human prostate cancer cell lines exhibited differential metabolic features when compared to the healthy prostate cell line RWPE-1.
  • After brief durations of PT-112 exposure, electron microscopy revealed noteworthy changes in prostate cancer cell mitochondrial structure in response to PT-112.

Promontory Therapeutics Receives U.S. Patent for Therapeutic Applications of PT-112 as an Immuno-Modulatory Agent

Retrieved on: 
Thursday, October 20, 2022

"This U.S. patent issuance underscores our approach to oncologic small molecule immunotherapies along with our robust clinical pipeline assessing PT-112 alone and in immunotherapy combination."

Key Points: 
  • "This U.S. patent issuance underscores our approach to oncologic small molecule immunotherapies along with our robust clinical pipeline assessing PT-112 alone and in immunotherapy combination."
  • The patent, titled "Phosphaplatin Compounds as Immuno-Modulatory Agents and Therapeutic Uses Thereof," was issued on Sept. 13, 2022 as U.S. Patent No.
  • Promontory Therapeutics Inc. is a privately held, clinical stage pharmaceutical company focused on small molecule immunotherapy.
  • To learn more about Promontory Therapeutics, visit the company's website here .

Promontory Therapeutics to Present Research on PT-112 in Prostate Cancer at the 34th EORTC-NCI-AACR Symposium

Retrieved on: 
Wednesday, October 12, 2022

PT-112 represents a highly potent inducer of this immunological form of cancer cell death.

Key Points: 
  • PT-112 represents a highly potent inducer of this immunological form of cancer cell death.
  • The PD-L1 combination Phase 2a study is ongoing in a dose confirmation cohort of non-small cell lung cancer (NSCLC) patients.
  • Promontory Therapeutics Inc. is a privately held, clinical stage pharmaceutical company focused on small molecule immunotherapy.
  • To learn more about Promontory Therapeutics, visit the company's website here .

Phosplatin Therapeutics Reports on PT-112's Selective Effects and Immunogenic Cell Death in Human Prostate Cancer Cell Models at the AACR Annual Meeting 2022

Retrieved on: 
Monday, April 11, 2022

"The result of this study provides a better understanding of PT-112's mechanism of action, in a manner that is linked to its established immunogenic cell death effects.

Key Points: 
  • "The result of this study provides a better understanding of PT-112's mechanism of action, in a manner that is linked to its established immunogenic cell death effects.
  • Sensitivity to PT-112 was assessed in human prostate cancer cell lines and the non-tumorigenic prostate cell line RWPE-1.
  • Key findings of the study included the following:
    PT-112 caused growth inhibition and cancer cell death without affecting healthy RWPE-1 cells.
  • Caspase inhibition reduced PT-112-induced cell death, with more mild effects seen with necroptosis inhibition, suggesting that cell death is primarily apoptotic.

Phosplatin Therapeutics Presents on PT-112 at the 2022 AACR Annual Meeting: Selective Intracellular Effects Leading to Immunogenic Cell Death (ICD) in Prostate Cancer Cell Models

Retrieved on: 
Thursday, March 10, 2022

The presentation will be held at the 2022 AACR Annual Meeting taking place on April 8-13, 2022 in New Orleans.

Key Points: 
  • The presentation will be held at the 2022 AACR Annual Meeting taking place on April 8-13, 2022 in New Orleans.
  • The work to be presented was generated by the company under a research collaboration with the Anel Lab at the University of Zaragoza, Spain.
  • The characterization of intracellular pathways leading to ICD and the adaptive immune response is an important research aim of the company, and a related peer-reviewed manuscript is under preparation.
  • PT-112 may represent the best-in-class inducer of this immunological form of cancer cell death.

Phosplatin Therapeutics Collaborates with the National Cancer Institute For Phase 2 Proof of Concept Study of PT-112 in Thymoma and Thymic Carcinoma

Retrieved on: 
Monday, November 15, 2021

Phosplatin and NCI anticipate opening the Phase 2 study soon, under a recently approved investigational new drug (IND) application.

Key Points: 
  • Phosplatin and NCI anticipate opening the Phase 2 study soon, under a recently approved investigational new drug (IND) application.
  • Phosplatin will provide NCI with PT-112 drug supply and support correlative research, and NCI will oversee enrollment and care of the study's intended 49 patients.
  • "Thymoma and thymic carcinoma are rare forms of cancer for which there is currently no FDA approved treatment.
  • The Phase 1 study in patients with relapsed or refractory multiple myeloma presented at ASH is the third completed Phase 1 study of PT-112.